Kodiak Sciences KOD Q3 2026: Pipeline on the Line With $88.7M in Cash
As seen on the 24/7 Wall St. homepage on November 12, 2026.
A $6.8 billion market cap now rests on $88.7 million of cash and a going-concern warning, even after a $69 million post-quarter stock sale. The loss came in slightly wider than expected on R&D of $58.3 million, but the real catalyst is December: the first Phase 3 KSI-101 readout, with the three-indication Zenkuda filing due by year-end.
Continue ReadingShow less
Kodiak Sciences reported a Q3 2026 GAAP loss of $1.05 per share, slightly wider than the $1.01 consensus estimate. The company generated no revenue, as it remains entirely precommercial, and R&D expenses climbed to $58.3 million from $50.5 million a year earlier as clinical activity accelerated across its late-stage programs.
The financial results themselves are almost secondary to what is coming in December. CEO Victor Perlroth confirmed that topline data from the first Phase 3 cohort of KSI-101 in the PEAK study are expected that month, and if successful, a BLA filing for KSI-101 would follow in the second quarter of 2027. Separately, a three-indication BLA for Zenkuda covering wet AMD, diabetic retinopathy, and retinal vein occlusion is on track for submission by year-end 2026, backed by five positive Phase 3 studies.
The cash position is where investors need to pay close attention. Kodiak ended the quarter with $88.7 million on hand and disclosed substantial going-concern doubt, meaning auditors have flagged uncertainty about the company's ability to fund ongoing operations. A post-quarter equity raise via an at-the-money offering brought in $69 million in net proceeds, extending the runway into 2027, but further dilution remains a live risk as the company awaits regulatory decisions.
Sponsored
Shareholders' equity fell nearly 47% year over year to $12.6 million, illustrating how heavily the company has leaned on equity financing to sustain its pipeline. Total assets stood at $209.4 million. The operating loss widened 7.6% to $67.1 million, partly offset by a non-cash, non-recurring gain tied to the termination of a Palo Alto building lease and $12.8 million of non-cash stock-based compensation included in the net loss figure.
The central tension for investors is a $6.8 billion market capitalization sitting atop a company with less than $90 million in cash, no revenue, and binary clinical outcomes due in the next two months. Perlroth described Zenkuda's DAYBREAK Phase 3 results as reinforcing its potential to become a first-line wet AMD therapy, citing a 24-week dosing interval for the majority of patients. Whether the KSI-101 readout in December delivers a similar result will go a long way toward determining whether that valuation holds.
Mentioned: KOD